Efectividad de la talidomida y la dexametasona en el tratamiento del mieloma múltiple resistente al tratamiento: estudio retrospectivo de 36 casos consecutivos / Effectivity of thalidomide and dexamethasone for the treatment of refractory multiple myeloma: a retrospective study of 36 consecutive cases
Hemos realizado un estudio retrospectivo de una serie de 36 casos consecutivos con MM pertinaz a los que hemos tratado con talidomida y dexametasona en segunda línea, con el objetivo de analizar la tasa de respuesta (objetivo primario), la supervivencia libre de progresión (SLP) y toxicidad (objetivos secundarios).
Resultados:
En nuestro estudio hemos encontrado una tasa de respuesta total del 55,6%, una mediana de SLP de 12,6 meses (intervalo de confianza del 95%, 4-21 meses). La SLP a los 6, 12 y 18 meses fue del 61,11, el 50 y el 22,22% respectivamente. El 30,6% de los pacientes presentaron neuropatía; el 11,11%, erupción cutánea y el 5,55%, enfermedad tromboembólica.
Multiple myeloma (MM) is a plasm-cell neoplasm characterized by a monoclonal protein in the serum or urine. Thalidomide is effective as second line treatment. Patients and
method:
We performed a retrospective study of 36 consecutive patients with refractory MM treated with thalidomide and dexamethasone as second line therapy, with the objective of analyzing the rate of response (primary end point), progression-free survival (PFS) and toxicity profiles (second end points).
Results:
In our study the overall response rate was 55.6%, with a median of PFS of 12.6 months (95% confidence interval 4-21 months). PFS at 6, 12 and 18 months was 61.11%, 50% and 22.22% respectively. 30.6% of the patients had neuropathy, 11.11% had rash and 5.55% had deep vein thrombosis.
Conclusions:
The combination of thalidomide and dexamethasone is an effective and safe second line treatment for refractory MM, with a manageable toxicity
